TITLE

Updated breast cancer guidelines

PUB. DATE
May 2005
SOURCE
CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1269
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents a summary of article reporting the updated breast cancer guidelines from the Steering Committee on Clinical Practice Guidelines for the Case and Treatment of Breast Cancer.
ACCESSION #
16900601

 

Related Articles

  • Clinical practice guidelines for the care and treatment of breast cancer: the management of chronic pain in patients with breast cancer (summary of the 2001 update). Emery, Chris; Gallagher, Romayne; Hugi, Maria; Levine, Mark // CMAJ: Canadian Medical Association Journal;10/30/2001, Vol. 165 Issue 9, p1218 

    Provides a summary of changes made by Health Canada's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer to the 1998 article 'Clinical practice guidelines for the care and treatment of breast cancer: 10. The management of chronic pain in patients with...

  • The prognostic association of health-related quality of life scores with survival in breast cancer. Digant Gupta; Joel Granick; James Grutsch; Christopher Lis // Supportive Care in Cancer;Apr2007, Vol. 15 Issue 4, p387 

    Abstract Goals of work  There is extensive data showing that health-related quality of life (HRQOL) tools measuring the activities of daily life provide prognostic information in cancer. However, similar information on HRQOL tools measuring patient satisfaction with their life is sparse....

  • Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience. Baxter, E.; Gondara, L.; Lohrisch, C.; Chia, S.; Gelmon, K.; Hayes, M.; Davidson, A.; Tyldesley, S. // Current Oncology;Jun2015, Vol. 22 Issue 3, p192 

    Background Proliferative scoring of breast tumours can guide treatment recommendations, particularly for estrogen receptor (er)-positive, her2-negative, T1-2, N0 disease. Our objectives were to estimate the proportion of such patients for whom proliferative indices [mitotic count (mc), Ki-67...

  • Response: Re: Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer. Fojo, Tito; Amiri-Kordestani, Laleh; Bates, Susan E. // JNCI: Journal of the National Cancer Institute;May2012, Vol. 104 Issue 9, p718 

    The authors respond to the comments made on their article "Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer." They appreciate the discusser for his concern with the trend in randomized clinical trials in oncology that allows patient access to experimental...

  • Cancer News Round-up.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p2 

    Presents cancer updates and developments in the U.S. as of November 2004. Positive efficacy results of GlaxoSmithKline PLC's investigatory breast cancer treatment in an ongoing phase II trial; Percentage increase in Dendreon Corp.'s shares after its experimental fast-tracked prostate cancer...

  • Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. M. E. Cazzaniga; G. Mustacchi; P. Pronzato; A. De Matteis; F. Di Costanzo; I. Floriani; On behalf of the NORA Study Group // Annals of Oncology;Dec2007, Vol. 18 Issue 12, p1976 

    Background: The NORA study is a prospective longitudinal cohort study aiming at investigating treatment in patients with early breast cancer. Here, we present the impact of the St Gallen recommendations on clinical practice. Patients and methods: We compared adjuvant strategies in patients...

  • ER Re-expression and Re-sensitization to Endocrine Therapies in ER-negative Breast Cancers. Joeli Brinkman; Dorraya El-Ashry // Journal of Mammary Gland Biology & Neoplasia;Mar2009, Vol. 14 Issue 1, p67 

    Abstract  Breast cancer is the leading cause of cancer amongst women in the westernized world. The presence or absence of ERα in breast cancers is an important prognostic indicator. About 30–40% of breast cancers lack detectable ERα protein. ERα− breast cancers are...

  • Endometrial Cancer Risk After Tamoxifen Therapy. Walling, Anne D. // American Family Physician;3/15/2001, Vol. 63 Issue 6, p1204 

    Presents a study by L. Bergman and others that assessed the relationship between tamoxifen therapy and the risk of endometrial cancer. Description of the study and its results; Conclusion that the survival benefits of tamoxifen in the treatment of women with breast cancer far outweigh the...

  • FDG-PET-CT in the early response evaluation for primary systemic therapy of breast cancer. Tőkés, Tímea; Torgyík, László; Kulka, Janina; Borka, Katalin; Szász, Attila; Tóth, Andrea; Harsányi, László; Lengyel, Zsolt; Györke, Tamás; Dank, Magdolna // Central European Journal of Medicine;Apr2014, Vol. 9 Issue 2, p306 

    Primary systemic therapy (PST) is a standard treatment for patients with locally advanced breast cancer. We report one of our patients to demonstrate the optimal use of FDG-PET-CT in the routine clinical workup during PST, especially when clinicians face contradictory clinical and pathological...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics